Oruka Therapeutics’ Finance VP Executes “Buy‑Then‑Sell” Play, Boosts Shares Amid Stock Slide

Insider Activity Spotlight: Oruka Therapeutics’ Finance Leader Swings the Trade

A Dual‑Edged Move by Senior VP, Finance

On May 18 2026, Agarwal Arjun, the Senior Vice President of Finance, executed a sizable buying spree of 2,000 shares at $12.50 and 5,833 shares at $34.39, immediately followed by a string of sales under a Rule 10b5‑1 plan. The sales ranged from 4,190 shares at $58.34 to 700 shares at $61.16, all at weighted averages that reflect a gradual uptick in the stock’s price. In parallel, Arjun exercised two blocks of employee stock options (2,000 and 5,833 shares), converting them into common equity and boosting his post‑transaction holdings to 118,000 and 64,167 shares, respectively.

What Does This Mean for Investors?

Arjun’s recent activity demonstrates a classic “buy‑then‑sell” pattern that can signal confidence in the company’s long‑term prospects while also providing liquidity for the executive. The sales under the 10b5‑1 plan are scheduled, mitigating insider‑trading concerns, yet the fact that they occur after a series of purchases could indicate that Arjun is positioning himself for a potential upside. The overall net effect is a slight increase in his stake (from 18,863 to 20,863 shares after the purchases) and a broader portfolio of options that could be exercised later if the stock continues to climb.

For the market, Arjun’s moves are a double‑edged sword: the purchases add buying pressure, potentially supporting the stock’s momentum, while the sales provide a modest supply that could temper short‑term price swings. Given Oruka’s recent 11 % weekly decline and a 13 % monthly slide, the insider’s confidence may help assuage nervous investors, especially as the company navigates its biotech pipeline and upcoming regulatory milestones.

Historical Patterns Paint a Picture of Cautious Optimism

Reviewing Arjun’s historic filings shows a pattern of disciplined buying and selective selling. In March 2026 he sold 395 shares at $41.30, and in January 2026 he bought 17,500 shares at no disclosed price, likely a block purchase at the market level. His exercise of over 70,000 options in January 2026 reflects a long‑term commitment to the company’s success. This blend of strategic purchases and scheduled sales is typical of seasoned finance executives who balance personal wealth building with fiduciary responsibility to shareholders.

Company‑Wide Insider Activity: A Broader Context

While Arjun’s activity is notable, other executives have been active as well. Chief Medical Officer Joana Goncalves has executed multiple buys and sells in the $6–$70 range, and Chief Operating Officer Laura Lee has sold a series of shares in the $7–$68 range on May 1, 2026. These patterns suggest a broader insider consensus that the company’s valuation is still undervalued relative to its pipeline potential. The simultaneous exercise of options and warrants by several officers further reinforces confidence in Oruka’s long‑term trajectory.

Takeaway for Stakeholders

Arjun’s latest transaction adds a layer of confidence for investors while also providing liquidity that could stabilize short‑term volatility. The disciplined use of Rule 10b5‑1 plans, combined with option exercises, signals that Oruka’s finance leadership is positioning itself for future growth. For investors, the insider activity may serve as a bullish barometer amid recent price declines, hinting that the company’s management believes the stock is poised for a rebound as clinical developments and market dynamics evolve.